Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

Company Leadership Changes - Sue Smith, Chief Commercial Officer, will be departing the organization [1] - Doug Gentilcore appointed as Senior Vice President, Head of DANYELZA Business Unit [4] - Doug Gentilcore brings over two decades of strategic leadership experience in the pharmaceutical industry [5] Product Information - DANYELZA® (naxitamab-gqgk) is indicated for the treatment of pediatric and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow [1] - DANYELZA® includes a Boxed Warning for serious infusion-related reactions and neurotoxicity [1] - DANYELZA is currently not approved for the treatment of osteosarcoma in any jurisdiction [2] Company Overview - Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic cancer products [3] - The Company's technologies include its investigational SADA PRIT Platform and bispecific antibodies generated using the Y-BiClone platform [3] - The Company's product pipeline includes the anti-GD2 therapy DANYELZA® [3] Future Plans and Expectations - Doug Gentilcore's experience is expected to be instrumental in the continued commercial expansion and growth of DANYELZA beyond pediatric oncology [5]